You are here

Impact Of RA Therapy Compliance On Patient-Reported Outcomes

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adults with moderate to severe RA who are currently using a DMARD

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE),
Non-Disease modifying anti-rheumatic disease (non-DMARD) use

NCT01438892
Pfizer
Completed
Impact Of RA Therapy Compliance On Patient-Reported Outcomes

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Impact Of RA Therapy Compliance On Patient-Reported Outcomes
Impact Of RA Therapy Compliance On Patient-Reported Outcomes
Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.
Cohort observational
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Adults with modertate to severe Rheumatoid Arthritis
Rheumatoid Arthritis
  • Drug: tDMARDs
    Traditional DMARDs for RA
  • Drug: biodmards
    Biologic DMARDs
  • tDMARDs Group
    traditional DMARDs
    Intervention: Drug: tDMARDs
  • Biologics group
    Biologics used in RA
    Intervention: Drug: biodmards
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
396
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults with moderate to severe RA who are currently using a DMARD

Exclusion Criteria:

  • Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01438892
A3921144
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now